These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21569446)

  • 1. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
    Mudge DW; Johnson DW; Hawley CM; Campbell SB; Isbel NM; van Eps CL; Petrie JJ
    BMC Nephrol; 2011 May; 12():20. PubMed ID: 21569446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral phosphate binders.
    Hutchison AJ
    Kidney Int; 2009 May; 75(9):906-14. PubMed ID: 19279554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
    Cozzolino M; Brancaccio D
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for hyperphosphatemia.
    Bellinghieri G; Santoro D; Savica V
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
    Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B;
    Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M
    Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J
    J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL; Wazny LD; Weinhandl ED
    Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.